This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
G&E Herbal Biotechnology Co., LTD
ClinicalTrials.gov Identifier:
NCT01796821
First received: February 18, 2013
Last updated: June 1, 2017
Last verified: June 2017
  Purpose
To evaluate the efficacy of SR-T100 gel by observing total clearance rate of treated baseline EGW(s) on the treated area.

Condition Intervention Phase
Condyloma Acuminata Genital Warts Condylomata Acuminata Venereal Warts Drug: Vehicle gel Drug: SR-T100 gel with 1.0 % SM Drug: SR-T100 gel with 2.3% SM Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator
Primary Purpose: Treatment
Official Title: A Double-Blind, Vehicle Controlled, Randomized, Phase II Study of SR-T100 Gel on External Genital Warts/Condyloma Acuminate (EGWs)

Resource links provided by NLM:


Further study details as provided by G&E Herbal Biotechnology Co., LTD:

Primary Outcome Measures:
  • Total clearance rate of baseline lesion(s) [ Time Frame: 16 weeks ]

Secondary Outcome Measures:
  • Total clearance rate of all lesion(s) [ Time Frame: 16 weeks ]
  • Period duration of achieving total clearance of baseline lesion(s) and new lesion(s) [ Time Frame: 16 weeks ]
  • Partial clearance rate [ Time Frame: 16 weeks ]
  • New lesion(s) occurrence rate [ Time Frame: 16 weeks ]
  • Recurrence rate in the 12-week follow-up time [ Time Frame: 28 weeks ]
  • Recurrence time period [ Time Frame: 28 weeks ]
  • Safety: evaluate the changes occurring from baseline to EOT visit [ Time Frame: 28 weeks ]
    including PE, vital sign, lab. test, local skin reaction, and adverse event, etc.


Estimated Enrollment: 111
Study Start Date: August 2014
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Vehicle gel
vehicle gel is used as a control group. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
Drug: Vehicle gel

Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.

Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.

Total application <1,500 mg gel per day.

Active Comparator: SR-T100 gel with 1.0 % SM
SR-T100 contains 1.0% SM. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
Drug: SR-T100 gel with 1.0 % SM

Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.

Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.

Total application <1,500 mg gel per day.

Active Comparator: SR-T100 gel with 2.3% SM
SR-T100 contains 2.3% SM. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
Drug: SR-T100 gel with 2.3% SM

Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.

Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.

Total application <1,500 mg gel per day.


Detailed Description:
A double-blind, randomized,vehicle-controlled, parallel-group, and dose-ranging study to evaluate the efficacy and safety of SR-T100 gel in patients with EGW(s). The primary efficacy endpoint will be defined as the proportion of patients whose baseline EGW(s) on the treated area achieve total clearance. The efficacy of SR-T100 gel in prevention of new EGW(s) occurrence will be evaluated. Distinct to existing medications for EGWs, SR-T100 gel possesses characteristics of high safety and low LSR causality. SR-T100 gel will be administered on EGW lesion(s) for clearance and on the surrounding clinical normal skin for prevention of new EGW(s) occurrence.
  Eligibility

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female; aged ≥ 20 years old.
  2. Patients who accept to enter the study by signing written informed consent.
  3. Each patient has 1 to 10 clinically diagnosed EGW(s). If patient has only 1 genital wart, the diameter of the genital wart must be no less than 5 mm.
  4. Female patients have lesion(s) on labia majora, labia minora, clitoris and/or groin.
  5. Male patients have lesion(s) on glans, shaft and/or foreskin.
  6. Each patient has at least 1 histologically proved EGW.
  7. Patients agree to apply the study medication on "clinical diagnosed lesion(s)" with occlusive dressing(s) once daily for at least 20 hours per day and "clinical normal skin on the treated area" thrice daily without occlusive dressing.
  8. Patients allow diagrammed mapping and photography on genital warts. And patients agree to be used of these data as part of the study data package.
  9. Patients in good general health condition (performance status ≤ 2 Eastern Cooperative Oncology Group (ECOG)).
  10. Female patients with child-bearing potential must take reliable contraception method(s) during the participation of the study.
  11. Patients must agree to use effective boundary barrier for birth control and re-infection of EGW

Exclusion Criteria:

  1. Patients with peri-anal warts.
  2. Male patients with warts on scrotum or perineum.
  3. Patients with other genital infections.
  4. Patients with internal genital warts (such as urethral, intra-vaginal, cervical, rectal, or intra-anal genital warts).
  5. Patients with active systemic infections.
  6. Patients with other genital diseases that may confound evaluation and treatment for genital warts.
  7. Patients with immuno-compromised medical condition.
  8. Patients have received investigational drug prior to 30 days of randomization visit.
  9. Patients with cancer or cancer history within 5 years of the randomization visit.
  10. Patients have on-going human papilloma virus (HPV) infection other than genital area.
  11. Patients with human immunodeficiency virus (HIV), venereal disease research laboratory (VDRL), or treponema pallidum particle agglutination assay (TPHA) positive result.
  12. Female patients have high-grade pathology in Papanicolaou smear tests based on Bethesda system.
  13. Female patients are pregnant or lactating.
  14. Patients have history of allergy or sensitivity to Solanum undatum plant extract, SM, or SR-T100 gel excipients including carbomer, propylene glycol, and triethanolamine.
  15. Patients with prohibited pre-medication or procedures shown below:

    1. Physical modalities, such as laser ablation, electrocautery or cryotherapy, for genital warts treatment on treated area within 4 weeks prior to randomization visit.
    2. Topical administered medication for genital warts treatment, such as polyphenon E, podophyllotoxin, imiquimod, or 5-fluorouracil (5-FU), within 12 weeks prior to randomization.
    3. Medications of cytotoxic, immunomodulator (inhaled and topical steroid not on ano-genital areas are not prohibited), systematic antiviral agent in 4 weeks prior to randomization visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01796821

Locations
Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung, Taiwan
Kaohsiung Municipal Ta-Tung Hospital
Kaohsiung, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
Sponsors and Collaborators
G&E Herbal Biotechnology Co., LTD
Investigators
Study Director: Kou-Wha Kuo, PhD G&E Herbal Biotechnology Co., LTD
Principal Investigator: Cheng-Yang Chou, M.D. National Cheng Kung University, Tainan, Taiwan
  More Information

Responsible Party: G&E Herbal Biotechnology Co., LTD
ClinicalTrials.gov Identifier: NCT01796821     History of Changes
Other Study ID Numbers: GESRTGWA
Study First Received: February 18, 2013
Last Updated: June 1, 2017

Keywords provided by G&E Herbal Biotechnology Co., LTD:
Condyloma acuminata
Genital warts
Condylomata acuminata
Venereal warts

Additional relevant MeSH terms:
Warts
Condylomata Acuminata
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Tumor Virus Infections
Skin Diseases, Infectious
Skin Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases

ClinicalTrials.gov processed this record on July 24, 2017